Low-Power Methodologies and Strategies in VLSI Circuits

Abstract

Due to the fact that low-power gadgets are currently dominating the electronics sectors, researchers are studying their design. Power management is a crucial parameter for designing VLSI circuits since it is essential for estimating the performance of devices, especially those utilized in biomedical and IoT applications. To achieve greater performance, designing a low-power system on a IC is becoming increasingly challenging due to the reduction in size of chip, increases in chip density, and rise in device complexity. Furthermore, for the less than 90 nm node, due to its increasingly complicated design, the total power factor on a chip is turning into a significant difficulty. Leakage current also has a significant effect on how low-power VLSI devices manage their power. Leakage and dynamic power reduction are increasingly being prioritized in VLSI circuit design in order to improve the battery life of electronic portable devices. The many methodologies, tactics, and power management schemes that can be employed for the design of low-power circuit systems are discussed in this chapter.

Clinico-Hematological Profile of Acute Leukemia Cases in Bihar: A Multiparameter Study in a Tertiary-Care Hospital

“…Minimal screening panels recommended for immunophenotyping of acute leukemia include CD10, CD19, CD7, CD5, CD13, CD33, CD117, CD34, HLA-DR, and CD45. 6 This finding was consistent with the study conducted by Preethi and Ghosh et al 19 21 According to Shahab and Raziq, AML-M4 was the most frequent subtype. 14…”

“…In our study, anemia is the most common hematological abnormality followed by thrombocytopenia and leucocytosis which has also been exemplified by Rathee et al 18 Maximum patients (59.0%) had hemoglobin of 6.1 to 10 g/dL followed by less than 6 g/dL in 35.5% of cases. Thrombocytopenia and leucocytosis were most common hematological abnormality in a study conducted by Preethi and Manisha et al 19 20 Anemia and leucocytosis were found to be significantly associated with acute leukemia patients ( p < 0.05).…”